WO2001021156A1 - Pharmaceutical chewing gum formulations - Google Patents

Pharmaceutical chewing gum formulations Download PDF

Info

Publication number
WO2001021156A1
WO2001021156A1 PCT/US2000/007991 US0007991W WO0121156A1 WO 2001021156 A1 WO2001021156 A1 WO 2001021156A1 US 0007991 W US0007991 W US 0007991W WO 0121156 A1 WO0121156 A1 WO 0121156A1
Authority
WO
WIPO (PCT)
Prior art keywords
chewing gum
medicament
chewing
individual
agent
Prior art date
Application number
PCT/US2000/007991
Other languages
French (fr)
Inventor
Ronald L. Ream
Christine L. Corriveau
William J. Wokas
Thomas J. Tongue
Michael J. Greenberg
Original Assignee
Wm. Wrigley Jr. Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wm. Wrigley Jr. Company filed Critical Wm. Wrigley Jr. Company
Priority to EP00919655A priority Critical patent/EP1181010A4/en
Priority to AU40308/00A priority patent/AU784112B2/en
Priority to JP2001524582A priority patent/JP2003509455A/en
Priority to CA002369515A priority patent/CA2369515A1/en
Publication of WO2001021156A1 publication Critical patent/WO2001021156A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/343Products for covering, coating, finishing, decorating
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/08Chewing gum characterised by the composition containing organic or inorganic compounds of the chewing gum base
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/18Chewing gum characterised by shape, structure or physical form, e.g. aerated products
    • A23G4/20Composite products, e.g. centre-filled, multi-layer, laminated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058Chewing gums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • A23G2200/04COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing vitamins, antibiotics, other medicaments

Definitions

  • the present invention generally relates to the delivery of medicaments and other agents. More specifically, the present invention relates to the delivery of medicaments and agents using chewing gum formulations.
  • agents to individuals can be used to treat diseases and as such are typically referred to as drugs or medicaments.
  • the drugs or medicaments can be used for prophylactic purposes.
  • agents to an individual for a variety of non- medical purposes including enhancing performance or mamtaining or initiating alertness.
  • agents to an individual run the gamut from stimulants such as caffeine to drugs such as analgesics, tranquilizers, cardiovascular products, insulin, etc. Some such agents are taken on an as needed basis while other agents must be taken at regular intervals by the individual.
  • drugs are administered parenterally or enterally.
  • parenteral administration is the administration of the drug intravenously directly into the blood stream.
  • Enteral refers to the administration of the drug into the gastrointestinal tract.
  • the goal of the drug administration is to move the drug from the site of administration towards the systemic circulation.
  • Passive diffusion is the transport across the cell membrane wherein the driving force for the movement is the concentration gradient of the solute. In orally administered drugs, this absorption occurs in the small intestines.
  • Facilitated diffusion is believed to be based on a carrier component that combines reversibly with the substrate molecule at the cell membrane exterior. The carrier substrate complex diffuses rapidly across the membrane with release of the substrate at the interior surface.
  • Active transport requires an energy expenditure by the cell and appears to be limited to agents with structural similarities to normal body constituents. These agents are usually absorbed from specific sites in the small intestines. Pinocytosis refers to the engulfing of particulars or fluid by a cell. It is believed to play a minor role in drug transport. Merck Manual, 16th Edition, pp. 2598-2599.
  • Drug absorption refers to the process of drug movement from the site of administration toward the systemic circulation.
  • Oral administration of drugs is by far the most common method.
  • drug absorption usually occurs due to the transport of cells across the membranes of the epithelial cells within the gastrointestinal tract.
  • Absorption after oral administration is confounded by numerous factors. These factors include differences down the alimentary cannel in: the luminal pH; surface area per luminal volume; perfusion of tissue, bile, and mucus flow; and the epithelial membranes. See Merck Manual at page 2599.
  • a further issue effecting the absorption of orally administered drugs is the form of the drug.
  • Most orally administered drugs are in the form of tablets or capsules. This is primarily for convenience, economy, stability, and patient acceptance. Accordingly, these capsules or tablets must be disintegrated or dissolved before absorption can occur. There are a variety of factors capable of varying or retarding disintegration of solid dosage forms. Further, there are a variety of factors that effect the dissolution rate and therefore determine the availability of the drug for absorption. See Merck Manual at page 2600.
  • Parental administration allows for the direct placement of the drug into the blood stream. This usually insures complete delivery of the dose to the general circulation. However, administration by a route that requires drug transfer through one or more biologic membranes to reach the blood stream precludes a guarantee that all of the drug will eventually be absorbed. Even with parental administration, because capillaries tend to be highly porous, the perfusion (blood flow/gram of tissue) is a major factor in the rate of absorption. Thus, the injection site can markedly influence a drags' absorption rate; e.g., the absorption rate of diazepam injected LM into a site with poor blood flow can be much slower than following an oral dose. See Merck Manual at page 2601.
  • Bioavailability is defined as the rate at which and the extent to which the active moiety (drug or metabolite) enters the general circulation, thereby gaining access to the site of action. Bioavailability depends upon a number of factors, including how a drug product is designed and manufactured, its physicochemical properties, and factors that relate to the physiology and pathology of the patient. See Merck Manual at page 2602.
  • Bioavailability considerations are most often encountered for orally a ⁇ ninistered drugs. Differences in bioavailability can have profound clinical significance.
  • parental administration does provide a method for eliminating a number of the variables that are present with oral administration
  • parental administration is not a preferable route.
  • parental administration requires the use of medical personnel and is just not warranted nor practical for the administration of most agents and drugs, e.g., analgesics.
  • agents and drugs e.g., analgesics.
  • parenteral administration is not preferred due to patient concerns including comfort, infection, etc., as well as the equipment and costs involved.
  • certain therapies require parenterally injected drugs. For example, research for decades has focused on an attempt to deliver insulin to an individual through a non-parental means. Despite such efforts today insulin is still only administered intravenously.
  • the present invention provides improved methods for delivering a medicament or agent to an individual.
  • chewing gum including a medicament or agent.
  • the medicament or agent is present within the chewing gum composition (the water soluble portion and or insoluble base portion). It has been found that by chewing the gum, the medicament or agent is released from the chewing gum. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.
  • Improved chewing gum formulations including medicaments and agents are also provided by the present invention.
  • the present invention provides a method of drug delivery comprising the steps of: providing a chewing gum that includes a medicament in the chewing gum composition; chewing the chewing gum to cause the medicament to be released from the chewing gum composition into the buccal cavity of the chewer; and continuing to chew the chewing gum thereby creating a fluid pressure causing the medicament to enter the systemic system of the chewer through the oral mucosa contained in the buccal cavity.
  • the chewing gum is chewed for at least 2 minutes.
  • the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antacids; antihistamines; decongestants; anti- inflammatories; antibiotics; antivirals; psychotherapeutic agents; insulin; and cardiovascular agents.
  • the chewing gum including the medicament is chewed at least twice a day. In an embodiment, two pieces of chewing gum are chewed at a time.
  • the present invention provides a method for reducing the amount of agent necessary to achieve an effect in an individual as compared to a typical agent that is swallowed.
  • the method comprises the steps of: providing a chewing gum including an agent that is typically swallowed by an individual to achieve a specific effect, the chewing gum including less than the typical amount of agent that is swallowed by the individual to achieve the effect; chewing the chewing gum and thereby causing the agent to be released into the salvia of the individual; and continuing to chew the chewing gum forcing the agent through the mucous membranes in a buccal cavity of the individual.
  • the agent is a medicament.
  • the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antihistamines; decongestants; antacids; anti- inflammatories; antibiotics; antivirals; psychotherapeutic agents; and cardiovascular agents.
  • the chewing gum is chewed for at least 2 minutes.
  • the chewing gum creates a saliva content of agent of at least 0.5 to about 5000 ppm depending on the medicament.
  • the agent is a stimulant.
  • the present invention provides a method of enhancing an individual's performance comprising the steps of: providing chewing gum including a performance enhancing amount of caffeine; and chewing the chewing gum not more than ten minutes before the performance.
  • the performance to be enhanced is athletic.
  • the performance to be enhanced is cognitive. In an embodiment, the performance to be enhanced is alertness.
  • the chewing gum is chewed not more than 5 minutes before the performance.
  • the present invention provides a method of delivering a medicament comprising the steps of: providing a chewing gum including a medicament; and chewing the chewing gum for at least 2 minutes.
  • the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antihistamines; decongestants; antacids; anti- inflammatories; antibiotics; antivirals; psychotherapeutic agents; insulin; and cardiovascular agents.
  • the present invention provides a method of increasing the stimulatory effect of a stimulant that has been previously ingested by an individual comprising the steps of: providing a chewing gum that contains the stimulant; and chewing the chewing gum causing the stimulant to be released by the chewing gum and forced into the oral mucosa of the individual. Accordingly, an advantage of the present invention is to provide new methods for delivering medicaments or agents to an individual.
  • an advantage of the present invention is to provide a method of delivering medicaments to an individual that provides for increase absorption and bioavailability as compared to medicaments that are designed to be absorbed in the GI tract.
  • an advantage of the present invention is to provide a method of administering a medicament or agent to an individual at a lower level than is typically administered orally while still achieving the same effect.
  • an advantage of the present invention is to provide a method for administering drags or agents to an individual that heretofore were administered parentally.
  • an advantage of the present invention is to provide a method for administering drags that is more palatable than current methods.
  • Another advantage of the present invention is to provide a method for enhancing the performance of an individual through the administration of an agent.
  • an advantage of the present invention is to provide an improved method for drag delivery.
  • an advantage of the present invention is to provide a method for creating a triggering effect that creates a synergistic effect with an agent that is present in the systemic circulation of the individual.
  • FIGURES Figure 1 illustrates graphically the results of Experiment No. 1 that is discussed supra.
  • FIG. 2 illustrates graphically the results of Experiment No. 2 that is discussed supra.
  • FIG. 3 illustrates graphically the results of Experiment No. 3 that is discussed supra.
  • the present invention provides improved methods for delivering medicaments and other agents to an individual as well as improved formulations including such medicaments and agents.
  • a medicament or agent is contained in a chewing gum formulation.
  • the medicament or agent is contained directly in the chewing gum composition, e.g., not in a coating around the chewing gum. Accordingly, as the chewing gum is chewed, the medicament or agent is released into the saliva. During continual chewing, the medicament or agent in the saliva is then forced due to the pressure created by the chewing through the oral mucosa in the buccal cavity.
  • the oral mucosa has a thin epithelium and a rich vascularity. Thus, the oral mucosa favors drag absorption.
  • caffeine is commonly used as a stimulant to alleviate the effects of sleep deprivation. It is almost completely metabolized in the liver and therefore classified as a low clearance, flow independent drug. This means its rate of inactivation is unaffected by delivery to the liver and can only be modified by a change in the hepatic enzyme activity.
  • medicaments and agents can be used in the chewing gum.
  • agents include, inter alia, stimulants such as caffeine.
  • medicaments include, inter alia, analgesics, antibiotics, antivirals, antiWstamines, anti-inflammatories, decongestants, antacids, muscle relaxants, psychotherapeutic agents, insulin, and cardiovascular agents.
  • the resultant chewing gum can be used to treat, inter alia: coughs; colds; motion sickness; allergies; fevers; pain; inflammation; sore throats; cold sores; sinus problems; diarrhea; diabetics; depression; anxiety; and other maladies and symptoms.
  • agents/medicaments include, by way of example and not limitation: caffeine; aspirin; acetaminophen; ibuprofen; hydroxycitric acid; chromium picolinate; phosphatidylserine; nicotine; insulin; Echinacea pu ⁇ urea; zinc; vitamin C; ginseng; kola nut; kaua kaua; and chamomile.
  • the agents or medicaments are contained in the chewing gum formulation at levels of approximately 50 micrograms to 500 milligrams. The specific levels will depend on the active ingredient.
  • chromium picolinate is the active ingredient in an embodiment, it would be present at a level of 50 micrograms per serving (2.8 grams stick of gum); aspirin would be preset at a level of 325 milligrams per 2.8/gram serving (stick).
  • the level of medicament or agent in the chewing gum formulation is selected so as to create, when the gum is chewed, a sufficiently high concentration of the medicament or agent in the saliva.
  • the level of the stimulant in the chewing gum should be such that it creates a saliva content of stimulant of approximately 15 to 440 ppm when the chewing gum is chewed for 2 minutes. At this level, a sufficient amount of stimulant will be delivered to the chewer to create the effects set forth in the application. If a medicament is used such as a medicinal (e.g., analgesics), sufficient medicinal should be present in the chewing gum to create a salvia content of approximately 1700 to approximately 4400 ppm after the chewing gum has been chewed for 2 minutes.
  • a medicament such as a medicinal (e.g., analgesics)
  • sufficient medicinal should be present in the chewing gum to create a salvia content of approximately 1700 to approximately 4400 ppm after the chewing gum has been chewed for 2 minutes.
  • the agent should be present in a sufficient amount to create a saliva content of approximately 85 to 1100 ppm when the chewing gum is chewed for 2 minutes.
  • the agents should be present in an amount to create a saliva content of approximately 0.5 to about 900 ppm when chewed for at least two minutes.
  • the agent is a vitamin or mineral (e.g., phosphatidy serine, vitamin C, and zinc)
  • the agent should be present in the amount to create a saliva content of the vitamin or mineral of approximately 10 to about 250 ppm when chewed for 2 minutes.
  • the dosing regiment will change.
  • the medicament is an analgesic
  • the chewing gum would be taken on an as needed basis.
  • the agent is a stimulant such as caffeine to be used to enhance performance than the chewing gum would be chewed, in a preferred embodiment ten minutes or less before the performance.
  • the medicament or agent can be contained in a variety of different chewing gum compositions.
  • the chewing gum including the medicament or agent may be based on a variety of different chewing gums that are known.
  • the chewing gums can be low or high moisture, sugar or sugarless, wax containing or wax free, low calorie (via high base or low calorie bulking agents), and/or may contain dental agents.
  • Chewing gum generally consists of a water insoluble gum base, a water soluble portion, and flavor.
  • the water soluble portion dissipates with a portion of the flavor of the gum over a period of time during chewing.
  • the gum base portion is retained in the mouth throughout the chew.
  • the insoluble gum base generally comprises elastomers, resins, fats and oils, softeners and inorganic fillers.
  • the gum base may or may not include wax.
  • the insoluble gum base can constitute approximately 5% to about 95% by weight of the chewing gum, more commonly the gum base comprises 10% to about 50% of the gum, and in some preferred embodiments approximately 25% to about 35%, by weight, of the chewing gum.
  • the chewing gum base of the present invention contains about 20% to about 60% by weight synthetic elastomer, about 0% to about 30% by weight natural elastomer, about 5% to about 55% by weight elastomer plasticizer, about 4% to about 35% by weight filler, about 5% to about 35% by weight softener, and optional minor amounts (about 1% or less by weight) of miscellaneous ingredients such as colorants, antioxidants, etc.
  • Synthetic elastomers may include, but are not limited to, polyisobutylene with GPC weight average molecular weight of about 10,000 to about 95,000, isobutylene- isoprene copolymer (butyl elastomer), styrene-butadiene, copolymers having styrene- butadiene ratios of about 1:3 to about 3:1, polyvinyl acetate having GPC weight average molecular weight of about 2,000 to about 90,000, polyisoprene, polyethylene, vinyl acetate - vinyl laurate copolymer having vinyl laurate content of about 5% to about 50% by weight of the copolymer, and combinations thereof.
  • Preferred ranges for polyisobutylene are 50,000 to 80,000 GPC weight average molecular weight and for styrene-butadiene are 1:1 to 1:3 bound styrene-butadiene, for polyvinyl acetate are 10,000 to 65,000 GBC weight average molecular weight with the higher molecular weight polyvinyl acetates typically used in bubble gum base, and for vinyl acetate- vinyl laurate, vinyl laurate content of 10-45%.
  • Natural elastomers may include natural rubber such as smoked or liquid latex and guayule as well as natural gums such as jelutong, lechi caspi, perillo, sorva, massaranduba balata, massaranduba chocolate, nispero, rosindinha, chicle, gutta hang kang, and combinations thereof.
  • the preferred synthetic elastomer and natural elastomer concentrations vary depending on whether the chewing gum in which the base is used is adhesive or conventional, bubble gum or regular gum, as discussed below.
  • Preferred natural elastomers include jelutong, chicle, sorva and massaranduba balata.
  • Elastomer plasticizers may include, but are not limited to, natural rosin esters such as glycerol esters or partially hydrogenated rosin, glycerol esters of polymerized rosin, glycerol esters of partially dimerized rosin, glycerol esters of rosin, pentaerythritol esters of partially hydrogenated rosin, methyl and partially hydrogenated methyl esters of rosin, pentaerythritol esters of rosin; synthetics such as te ⁇ ene resins derived from alpha-pinene, beta-pinene, and/or d-limonene; and any suitable combinations of the foregoing.
  • the preferred elastomer plasticizers will also vary depending on the specific application, and on the type of elastomer which is used.
  • Fillers/texturizers may include magnesium and calcium carbonate, ground limestone, silicate types such as magnesium and aluminum silicate, clay, alumina, talc, titanium oxide, mono-, di- and tri-calcium phosphate, cellulose polymers, such as wood, and combinations thereof.
  • Softeners/emulsifiers may include tallow, hydrogenated tallow, hydrogenated and partially hydrogenated vegetable oils, cocoa butter, glycerol monostearate, glycerol triacetate, lecithin, mono-, di- and triglycerides, acetylated monoglycerides, fatty acids (e.g. stearic, palmitic, oleic and linoleic acids), and combinations thereof.
  • Colorants and whiteners may include FD&C-type dyes and lakes, fruit and vegetable extracts, titanium dioxide, and combinations thereof.
  • the base may or may not include wax.
  • An example of a wax-free gum base is disclosed in U.S. Patent No. 5,286,500, the disclosure of which is inco ⁇ orated herein by reference.
  • a typical chewing gum composition includes a water soluble bulk portion and one or more flavoring agents.
  • the water soluble portion can include bulk sweeteners, high intensity sweeteners, flavoring agents, softeners, emulsifiers, colors, acidulants, fillers, antioxidants, and other components that provide desired attributes.
  • Softeners are added to the chewing gum in order to optimize the chewability and mouth feel of the gum.
  • the softeners which are also known as plasticizers and plasticizing agents, generally constitute between approximately 0.5% to about 15% by weight of the chewing gum.
  • the softeners may include glycerin, lecithin, and combinations thereof.
  • Aqueous sweetener solutions such as those containing sorbitol, hydrogenated starch hydrolysates, corn syrup and combinations thereof, may also be used as softeners and binding agents in chewing gum.
  • Bulk sweeteners include both sugar and sugarless components. Bulk sweeteners typically constitute about 5% to about 95% by weight of the chewing gum, more typically, about 20% to about 80% by weight, and more commonly, about 30% to about 60% by weight of the gum. Sugar sweeteners generally include saccharide-containing components commonly known in the chewing gum art, including but not limited to, sucrose, dextrose, maltose, dextrin, dried invert sugar, fructose, levulose, glactose, corn syrup solids, and the like, alone or in combination.
  • Sugarless sweeteners include, but are not limited to, sugar alcohols such as sorbitol, mannitol, xylitol, hydrogenated starch hydrolysates, maltitol, and the like, alone or in combination.
  • High intensity artificial sweeteners can also be used, alone or in combination, with the above.
  • Preferred sweeteners include, but are not limited to, sucralose, aspartame, salts of acesulfame, altitame, saccharin and its salts, cyclamic acid and its salts, glycerrhizinate, dihydrochalcones, thaumatin, monellin, and the like, alone or in combination.
  • Such techniques as wet granulation, wax granulation, spray drying, spray chilling, fluid bed coating, coacervation, and fiber extension may be used to achieve the desired release characteristics.
  • Combinations of sugar and/or sugarless sweeteners may be used in chewing gum. Additionally, the softener may also provide additional sweetness such as with aqueous sugar or alditol solutions.
  • a low caloric bulking agent can be used.
  • low caloric bulking agents include: polydextrose; Raftilose, Raftilin; Fructooligosaccharides (NutraFlora); Palatinose oligosaccharide; Guar Gum Hydrolysate (Sun Fiber); or indigestible dextrin (Fibersol).
  • other low calorie bulking agents can be used.
  • flavoring agents can also be used, if desired.
  • the flavor can be used in amounts of about 0.1 to about 15 weight percent of the gum, and preferably, about 0.2%) to about 5% by weight.
  • Flavoring agents may include essential oils, synthetic flavors or mixtures thereof including, but not limited to, oils derived from plants and fruits such as citrus oils, fruit essences, peppermint oil, spearmint oil, other mint oils, clove oil, oil of wintergreen, anise and the like. Artificial flavoring agents and components may also be used. Natural and artificial flavoring agents may be combined in any sensorially acceptable fashion.
  • the medicament or agent is water soluble in the chewing gum, it preferably will include a base/emulsifier system which leads to the desired concentration of the medicament in the saliva (more hydrophilic balance). If the medicament or agent is water insoluble, the chewing gum preferably includes a base/emulsifier system which leads to the desired concentration of the medicament in the saliva (more lipophilic balance).
  • the agent or medicament is added, preferably, early on in the mix. The smaller the amount of active ingredient used, the more necessary it becomes to preblend that particular ingredient to assume uniform distribution throughout the batch of gum. Whether a preblend is used or not, in a preferred embodiment, the agent or medicament should be added within the first five minutes of mixing.
  • examples of some chewing gum formulations including a medicament or agent are as follows:
  • Formula can be modified to include caffeine.
  • examples testing the chewing gum formulation of the present invention are as follows:
  • the subjects were instructed that they were to have caffeine, alcohol or other drug use for at least 8 hours prior to test. No tobacco products for at least 2 hours prior to test. Subjects must have been awake and active for at least 8 but no more than 16 hours prior to starting the test. Subjects will be required to complete a 10 part questionnaire at the following time points (-20, -10, -5 and at 2, 5, 10, 15, 20, 30, 40 and 1 hour after starting to chew the gum. Appropriate analysis of comparison of each individual item of the test and grouped analysis for both positive and negative affect.
  • Figure 1 graphically illustrates alertness versus time. These results demonstrate that by 5 minutes the subject reported that they were quite a bit alert. The alertness response was based on reference Panas feeling and emotion scale.
  • a randomized, single-dose, two-way crossover study was conducted with six (6) healthy, adult, non-tobacco-using male subjects.
  • a single 100 mg does of caffeine was administered in each study period after an overnight fast.
  • the test treatment was two 50mg caffeine chewing gum pieces (sticks), which were chewed for 15 minutes and removed.
  • the reference treatment was one 1 OOmg chewable No-Doz® tablet, which was chewed and swallowed.
  • One of the treatments was given in each period; the order of administration was according to the dosing randomization schedule. There was a 7-day washout between treatments.
  • Plasma samples were collected pre-dose and over 15 hours after each dose. Plasma concentrations of caffeine were measured by a fully validated chromatographic procedure. Samples from subject with measurable pre-dose levels of caffeine were corrected for these levels. Pharmacokinetic parameters were calculated from the adjusted data and statistical analyses were performed to compare the test and reference treatments.
  • the 6 subjects who participated in this study were healthy males, in the age range of 25 to 35 years, and within 15% of their ideal weight as specified in the protocol.
  • Test (A) Two 50mg chewing gum sticks, Amurol Confections Co.
  • Admimsfration The subjects received the test and reference after an overnight fast. The subjects randomized to the test first drank 240 ml of room temperature tap water. The chewing gum pieces were then chewed for 15 minutes and deposited into a labeled vial. The subjects randomized to the reference chewed the No-Doz® tablets and then drank 240 ml of room temperature tap water. The order of treatment administration was according to the randomization schedule. All doses were administered at one-minute intervals beginning at 0700 hours. A thorough mouth check was performed to ensure that the chewable tablet was swallowed.
  • Blood pressure (sitting), pulse rate, respiratory rate and oral temperature were measured before each dosing.
  • the investigator considered the measurements of all subjects as clinically acceptable for dosing.
  • Blood pressure and pulse rate measurements (sitting) were obtained approximately one hour after each dose and prior to release in each study period to monitor the health of the subjects. Measurements were repeated if clinically warranted.
  • a blood sample was collected at the time of the last sample of the study for a hematocrit determination. All hematocrit values were within 10% of the normal range (41-50%).
  • A. Quality Control. Standards and Controls Calibration standards were prepared spiking a pool of human, interference-free, heparinized plasma with caffeine (USP Reference, Lot I). The plasma was obtained from Interstate Blood Bank (Memphis, TN). The standards were prepared to contain 0.050, 0.100, 0.200, 0.500, 1.00, 2.00 and 5.00 ⁇ g/ml of caffeine. The caffeine standards and controls were divided into 2.5ml aliquots and stored in the laboratory in polypropylene snap-cap tubes frozen to at least -19°C. The pre-study within-run coefficient of variation ranged from 0.915% to 2.54%.
  • the response ratio for each remaining non-zero standard was plotted as a function of concentration.
  • a linear regression was calculated (R/S 1, version 4.3) by the method of least- squares using (1/CONC) 2 as a weighting factor. With this calibration line, a calculated concentration was determined for each standard sample. Any standard differing by more than ⁇ 25%) from its theoretical value was excluded from the regression and the regression was recalculated.
  • the analyte concentrations in the samples and the controls were estimated from the calibration line by use of the equation: (RATIO - LNTERCEPT)/SLOPE. The analytical run was considered acceptable if 4 of 6 controls passed established acceptance criteria and that at least one control sample was acceptable within each concentration range.
  • Controls within an analytical run were considered acceptable if the low control values differed by no more than ⁇ 20% and the middle and high controls differed by no more than ⁇ 15% from their theoretical values.
  • the concentrations o the controls were graphically displayed to permit visual confirmation of acceptability and identification of trends.
  • Sample Storage and Stability The plasma samples, which were collected in the clinic were transferred to the laboratory and stored frozen to at least -19°C until analyzed. Samples were not identified to the analysts by treatment group. All subjects' samples were analyzed within 19 days of the initial sampling. The frozen stability of caffeine in plasma has been confirmed for 138 days.
  • Peak Identification The retention times of the analyte and the internal standard were identified, in any given analytical run, by comparison to stock standards chromatographed at the beginning of the run and to processed standards chromatographed through the run.
  • Pharmacokinetic parameters were calculated using the actual rather than the scheduled time of sample collection. Graphical presentations of individual subject results also used the exact times of sample collection. Graphical presentations of mean results used the scheduled times of sample collection.
  • Peak concentration (Cmax) was the observed maximum value (corrected for pre- dose levels, if necessary) during the collection period of 0 to 15 hours.
  • the time to peak concentration (Tmax) was the time at which Cmax was observed (or first observed, if more than one peak was present).
  • the apparent first-order elimination rate (Ke) was estimated as the absolute value of the slope of the regression line for the terminal log- linear concentration- time values. The values included in the regression analyses were determined by examination of the individual subject plots of natural logarithm of concentration against time. Elimination half-life (t-'/i) was calculated as 0.693/Ke.
  • AUC Area under the curve
  • C the time of the last non-zero concentration
  • AUCinf Area to infinite time
  • the caffeine chewing gum pieces appear to have a much faster rate of abso ⁇ tion that the No-Doz® chewable tablets.
  • the areas and peak concentrations of the chewing gum were less than half that of No-Doz®, and the time to reach a peak for the gum was
  • Table 1 Comparisons of caffeine results for 50mg chewing gum pieces (Test) vs. lOOmg No-Doz® chewable tablets (Reference) administered as a single lOOmg dose under fasting conditions to 6 subjects.
  • Test Ref Ratio calculated as Test mean divided by Reference mean. 3 Power to detect a difference of 20% (original data) or a ratio of 1.25 (In- transformed data).
  • Figure 3 illustrates graphically % caffeine remaining over chew-out time in minutes.

Abstract

Methods and chewing gums for delivering a medicament or agent to an individual are provided. The chewing gum includes a medicament or agent. The medicament or agent is present within the chewing gum composition (the water soluble portion and/or insoluble base portion). It has been found that by chewing the gum, the medicament or agent is released from the chewing gum. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

Description

S P E C I F I C A T I O N
TITLE
"PHARMACEUTICAL CHEWING GUM FORMULATIONS"
BACKGROUND OF THE INVENTION
The present invention generally relates to the delivery of medicaments and other agents. More specifically, the present invention relates to the delivery of medicaments and agents using chewing gum formulations.
It is of course known to provide agents to individuals for various purposes. These agents can be used to treat diseases and as such are typically referred to as drugs or medicaments. Likewise, the drugs or medicaments can be used for prophylactic purposes. Still, it is known to provide agents to an individual for a variety of non- medical purposes including enhancing performance or mamtaining or initiating alertness. There are a great variety of such agents. These agents run the gamut from stimulants such as caffeine to drugs such as analgesics, tranquilizers, cardiovascular products, insulin, etc. Some such agents are taken on an as needed basis while other agents must be taken at regular intervals by the individual.
Typically, drugs (medicaments) are administered parenterally or enterally. Of course, parenteral administration is the administration of the drug intravenously directly into the blood stream. Enteral refers to the administration of the drug into the gastrointestinal tract. In either case, the goal of the drug administration is to move the drug from the site of administration towards the systemic circulation.
Except when given intravenously, a drug must traverse several semipermeable cell membranes before reaching general circulation. These membranes act as a biological barrier that inhibits the passage of drug molecules. There are believed to be four processes by which drugs move across a biological barrier: passive diffusion; facilitated diffusion; active transport; and pinocytosis.
Passive diffusion is the transport across the cell membrane wherein the driving force for the movement is the concentration gradient of the solute. In orally administered drugs, this absorption occurs in the small intestines. Facilitated diffusion is believed to be based on a carrier component that combines reversibly with the substrate molecule at the cell membrane exterior. The carrier substrate complex diffuses rapidly across the membrane with release of the substrate at the interior surface. Active transport requires an energy expenditure by the cell and appears to be limited to agents with structural similarities to normal body constituents. These agents are usually absorbed from specific sites in the small intestines. Pinocytosis refers to the engulfing of particulars or fluid by a cell. It is believed to play a minor role in drug transport. Merck Manual, 16th Edition, pp. 2598-2599.
In determining the efficacy of a drug and the effectiveness of the use of a drug to treat a disease, drug absorption is a critical concern. Drug absorption refers to the process of drug movement from the site of administration toward the systemic circulation.
Oral administration of drugs is by far the most common method. When administered orally, drug absorption usually occurs due to the transport of cells across the membranes of the epithelial cells within the gastrointestinal tract. Absorption after oral administration is confounded by numerous factors. These factors include differences down the alimentary cannel in: the luminal pH; surface area per luminal volume; perfusion of tissue, bile, and mucus flow; and the epithelial membranes. See Merck Manual at page 2599.
A further issue effecting the absorption of orally administered drugs is the form of the drug. Most orally administered drugs are in the form of tablets or capsules. This is primarily for convenience, economy, stability, and patient acceptance. Accordingly, these capsules or tablets must be disintegrated or dissolved before absorption can occur. There are a variety of factors capable of varying or retarding disintegration of solid dosage forms. Further, there are a variety of factors that effect the dissolution rate and therefore determine the availability of the drug for absorption. See Merck Manual at page 2600.
Parental administration allows for the direct placement of the drug into the blood stream. This usually insures complete delivery of the dose to the general circulation. However, administration by a route that requires drug transfer through one or more biologic membranes to reach the blood stream precludes a guarantee that all of the drug will eventually be absorbed. Even with parental administration, because capillaries tend to be highly porous, the perfusion (blood flow/gram of tissue) is a major factor in the rate of absorption. Thus, the injection site can markedly influence a drags' absorption rate; e.g., the absorption rate of diazepam injected LM into a site with poor blood flow can be much slower than following an oral dose. See Merck Manual at page 2601.
Not only is drug absorption an issue in drug delivery but also the bioavailability of the drug is also critical. Bioavailability is defined as the rate at which and the extent to which the active moiety (drug or metabolite) enters the general circulation, thereby gaining access to the site of action. Bioavailability depends upon a number of factors, including how a drug product is designed and manufactured, its physicochemical properties, and factors that relate to the physiology and pathology of the patient. See Merck Manual at page 2602.
When a drug rapidly dissolves from a drug product and readily passes across membranes, absorption from most site administration tends to be complete. This is not always the case for drugs given orally. Before reaching the vena cava, the drug must move down the alimentary cannel and pass through the gut wall and liver, which are common sites of drug metabolism. Thus, the drug may be metabolized before it can be measured in the general circulation. This cause of a decrease in drug input is called the first pass effect. A large number of drugs show low bioabilities owing to an extensive first pass metabolism. The two other most frequent causes of low bioavailability are insufficient time in the GI tract and the presence of competing reactions. See Merck Manual at page 2602.
Bioavailability considerations are most often encountered for orally aα^ninistered drugs. Differences in bioavailability can have profound clinical significance.
Although parental administration does provide a method for eliminating a number of the variables that are present with oral administration, parental administration is not a preferable route. Typically, parental administration requires the use of medical personnel and is just not warranted nor practical for the administration of most agents and drugs, e.g., analgesics. Even when required parenteral administration is not preferred due to patient concerns including comfort, infection, etc., as well as the equipment and costs involved. However, despite best efforts certain therapies require parenterally injected drugs. For example, research for decades has focused on an attempt to deliver insulin to an individual through a non-parental means. Despite such efforts today insulin is still only administered intravenously.
There is therefore a need for an improved method of delivering drugs and agents to an individual.
SUMMARY OF THE INVENTION
The present invention provides improved methods for delivering a medicament or agent to an individual. To this end, chewing gum is provided including a medicament or agent. The medicament or agent is present within the chewing gum composition (the water soluble portion and or insoluble base portion). It has been found that by chewing the gum, the medicament or agent is released from the chewing gum. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system. Improved chewing gum formulations including medicaments and agents are also provided by the present invention.
To this end, the present invention provides a method of drug delivery comprising the steps of: providing a chewing gum that includes a medicament in the chewing gum composition; chewing the chewing gum to cause the medicament to be released from the chewing gum composition into the buccal cavity of the chewer; and continuing to chew the chewing gum thereby creating a fluid pressure causing the medicament to enter the systemic system of the chewer through the oral mucosa contained in the buccal cavity.
In an embodiment, the chewing gum is chewed for at least 2 minutes.
In an embodiment, the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antacids; antihistamines; decongestants; anti- inflammatories; antibiotics; antivirals; psychotherapeutic agents; insulin; and cardiovascular agents.
In an embodiment, the chewing gum including the medicament is chewed at least twice a day. In an embodiment, two pieces of chewing gum are chewed at a time.
In a further embodiment, the present invention provides a method for reducing the amount of agent necessary to achieve an effect in an individual as compared to a typical agent that is swallowed. The method comprises the steps of: providing a chewing gum including an agent that is typically swallowed by an individual to achieve a specific effect, the chewing gum including less than the typical amount of agent that is swallowed by the individual to achieve the effect; chewing the chewing gum and thereby causing the agent to be released into the salvia of the individual; and continuing to chew the chewing gum forcing the agent through the mucous membranes in a buccal cavity of the individual.
In an embodiment of the method, the agent is a medicament. In an embodiment of the method, the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antihistamines; decongestants; antacids; anti- inflammatories; antibiotics; antivirals; psychotherapeutic agents; and cardiovascular agents.
In an embodiment of the method, the chewing gum is chewed for at least 2 minutes.
In an embodiment of the method, the chewing gum creates a saliva content of agent of at least 0.5 to about 5000 ppm depending on the medicament.
In an embodiment of the method, the agent is a stimulant.
In another embodiment, the present invention provides a method of enhancing an individual's performance comprising the steps of: providing chewing gum including a performance enhancing amount of caffeine; and chewing the chewing gum not more than ten minutes before the performance.
In an embodiment, the performance to be enhanced is athletic.
In an embodiment, the performance to be enhanced is cognitive. In an embodiment, the performance to be enhanced is alertness.
In an embodiment, the chewing gum is chewed not more than 5 minutes before the performance.
In still a further embodiment, the present invention provides a method of delivering a medicament comprising the steps of: providing a chewing gum including a medicament; and chewing the chewing gum for at least 2 minutes. In an embodiment, the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antihistamines; decongestants; antacids; anti- inflammatories; antibiotics; antivirals; psychotherapeutic agents; insulin; and cardiovascular agents. Yet further, the present invention provides a method of increasing the stimulatory effect of a stimulant that has been previously ingested by an individual comprising the steps of: providing a chewing gum that contains the stimulant; and chewing the chewing gum causing the stimulant to be released by the chewing gum and forced into the oral mucosa of the individual. Accordingly, an advantage of the present invention is to provide new methods for delivering medicaments or agents to an individual.
Still further, an advantage of the present invention is to provide a method of delivering medicaments to an individual that provides for increase absorption and bioavailability as compared to medicaments that are designed to be absorbed in the GI tract.
Further, an advantage of the present invention is to provide a method of administering a medicament or agent to an individual at a lower level than is typically administered orally while still achieving the same effect.
Furthermore, an advantage of the present invention is to provide a method for administering drags or agents to an individual that heretofore were administered parentally.
Additionally, an advantage of the present invention is to provide a method for administering drags that is more palatable than current methods.
Another advantage of the present invention is to provide a method for enhancing the performance of an individual through the administration of an agent.
Moreover, an advantage of the present invention is to provide an improved method for drag delivery.
Still, an advantage of the present invention is to provide a method for creating a triggering effect that creates a synergistic effect with an agent that is present in the systemic circulation of the individual.
Additional features and advantages of the present invention will be described in and apparent from the detailed description of the presently preferred embodiments and the figures.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 illustrates graphically the results of Experiment No. 1 that is discussed supra.
Figure 2 illustrates graphically the results of Experiment No. 2 that is discussed supra.
Figure 3 illustrates graphically the results of Experiment No. 3 that is discussed supra.
DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS
The present invention provides improved methods for delivering medicaments and other agents to an individual as well as improved formulations including such medicaments and agents. Pursuant to the present invention, a medicament or agent is contained in a chewing gum formulation. In contrast to prior such formulations, the medicament or agent is contained directly in the chewing gum composition, e.g., not in a coating around the chewing gum. Accordingly, as the chewing gum is chewed, the medicament or agent is released into the saliva. During continual chewing, the medicament or agent in the saliva is then forced due to the pressure created by the chewing through the oral mucosa in the buccal cavity. The oral mucosa has a thin epithelium and a rich vascularity. Thus, the oral mucosa favors drag absorption. In contrast to a typically orally ingested drag, wherein the solution is in contact too briefly for absoφtion to be appreciable through the oral mucosa, it is believed that during chewing, the agent and/or medicament remains in the buccal cavity and is forced through the oral mucosa. Also it has been surprisingly found that an increase in the absoφtion of the drag is achieved as well as an increase in the bioavailability of the drag as compared to typical oral administration. It has been found that the drag or agent is absorbed much quicker than if it was swallowed as in a typical oral administration. Indeed, the absoφtion approaches that of a parental administration, and bioavailability is also much greater than oral administration.
It has also been suφrisingly found that less medicament or agent can be placed in the chewing gum than is typically orally administered to an individual to achieve an effect and the same bioequivalence can be achieved. In fact, it has been suφrisingly found that in certain instances, for at least certain drags and agents, the administration of the medicament or agent using chewing gum through the buccal cavity can provide an increase effect even as compared to parenteral administration.
For example, caffeine is commonly used as a stimulant to alleviate the effects of sleep deprivation. It is almost completely metabolized in the liver and therefore classified as a low clearance, flow independent drug. This means its rate of inactivation is unaffected by delivery to the liver and can only be modified by a change in the hepatic enzyme activity.
The pharmacokinetics of caffeine have been well documented and there is no significant difference between oral and intravenous administration. However, data set forth in detail below, suggests that the absoφtion rate constant (Ka) is significantly increased when caffeine is administered through chewing gum. This means that the caffeine is moving into the systemic circulation at a significantly faster rate. A similar change in the onset of dynamic response has also been noted, e.g., alertness and performance. It has additionally been suφrisingly found that for at least certain agents that placing the agent in the chewing gum can have a triggering effect on the agent that may be in the systemic circulation. For example, it has been found that with respect to caffeine that is ingested orally, that after the ingestion of a certain amount of caffeine, and the elapse of a certain period of time, that further ingestion of caffeine has a negligible effect on the individual. However, upon chewing gum with caffeine there has been observed a triggering effect that appears to create a synergistic effect with the caffeine that is in the systemic circulation. It is believed that this triggering effect will also be present with other agents, e.g., analgesics.
It is envisioned, that a variety of different medicaments and agents can be used in the chewing gum. For example, such agents include, inter alia, stimulants such as caffeine. Generally, such medicaments include, inter alia, analgesics, antibiotics, antivirals, antiWstamines, anti-inflammatories, decongestants, antacids, muscle relaxants, psychotherapeutic agents, insulin, and cardiovascular agents. It is envisioned, that depending on the medicament, the resultant chewing gum can be used to treat, inter alia: coughs; colds; motion sickness; allergies; fevers; pain; inflammation; sore throats; cold sores; sinus problems; diarrhea; diabetics; depression; anxiety; and other maladies and symptoms. Specific agents/medicaments include, by way of example and not limitation: caffeine; aspirin; acetaminophen; ibuprofen; hydroxycitric acid; chromium picolinate; phosphatidylserine; nicotine; insulin; Echinacea puφurea; zinc; vitamin C; ginseng; kola nut; kaua kaua; and chamomile. Preferably, the agents or medicaments are contained in the chewing gum formulation at levels of approximately 50 micrograms to 500 milligrams. The specific levels will depend on the active ingredient. For example, if chromium picolinate is the active ingredient in an embodiment, it would be present at a level of 50 micrograms per serving (2.8 grams stick of gum); aspirin would be preset at a level of 325 milligrams per 2.8/gram serving (stick).
The level of medicament or agent in the chewing gum formulation is selected so as to create, when the gum is chewed, a sufficiently high concentration of the medicament or agent in the saliva.
For example, when the agent is a stimulant such as nicotine or caffeine, the level of the stimulant in the chewing gum should be such that it creates a saliva content of stimulant of approximately 15 to 440 ppm when the chewing gum is chewed for 2 minutes. At this level, a sufficient amount of stimulant will be delivered to the chewer to create the effects set forth in the application. If a medicament is used such as a medicinal (e.g., analgesics), sufficient medicinal should be present in the chewing gum to create a salvia content of approximately 1700 to approximately 4400 ppm after the chewing gum has been chewed for 2 minutes. For a botanicals (e.g., chamomile, kava, kola, nut, ginseng, and Echinacea), the agent should be present in a sufficient amount to create a saliva content of approximately 85 to 1100 ppm when the chewing gum is chewed for 2 minutes. For a metabolizer, for example, chromium picolineate and hydroxi-chitic acid, the agents should be present in an amount to create a saliva content of approximately 0.5 to about 900 ppm when chewed for at least two minutes. If the agent is a vitamin or mineral (e.g., phosphatidy serine, vitamin C, and zinc), the agent should be present in the amount to create a saliva content of the vitamin or mineral of approximately 10 to about 250 ppm when chewed for 2 minutes.
Pursuant to the present invention, depending on the agent or medicament, the dosing regiment will change. For example, if the medicament is an analgesic, the chewing gum would be taken on an as needed basis. Of course, similar to the oral administration of an analgesic, there would be restrictions on the number of pieces of chewing gum, chewed, for example, not more often than one stick every four hours and not more often than four to five times a day. If the agent is a stimulant such as caffeine to be used to enhance performance than the chewing gum would be chewed, in a preferred embodiment ten minutes or less before the performance. As set forth below in the experiment, it has been suφrisingly found that another 5 minutes of chewing a chewing gum including caffeine a high level of alertness is achieved. The medicament or agent can be contained in a variety of different chewing gum compositions. Referring now to the chewing gum, pursuant to the present invention, the chewing gum including the medicament or agent may be based on a variety of different chewing gums that are known. For example, the chewing gums can be low or high moisture, sugar or sugarless, wax containing or wax free, low calorie (via high base or low calorie bulking agents), and/or may contain dental agents.
Chewing gum generally consists of a water insoluble gum base, a water soluble portion, and flavor. The water soluble portion dissipates with a portion of the flavor of the gum over a period of time during chewing. The gum base portion is retained in the mouth throughout the chew. The insoluble gum base generally comprises elastomers, resins, fats and oils, softeners and inorganic fillers. The gum base may or may not include wax. The insoluble gum base can constitute approximately 5% to about 95% by weight of the chewing gum, more commonly the gum base comprises 10% to about 50% of the gum, and in some preferred embodiments approximately 25% to about 35%, by weight, of the chewing gum.
In an embodiment, the chewing gum base of the present invention contains about 20% to about 60% by weight synthetic elastomer, about 0% to about 30% by weight natural elastomer, about 5% to about 55% by weight elastomer plasticizer, about 4% to about 35% by weight filler, about 5% to about 35% by weight softener, and optional minor amounts (about 1% or less by weight) of miscellaneous ingredients such as colorants, antioxidants, etc.
Synthetic elastomers may include, but are not limited to, polyisobutylene with GPC weight average molecular weight of about 10,000 to about 95,000, isobutylene- isoprene copolymer (butyl elastomer), styrene-butadiene, copolymers having styrene- butadiene ratios of about 1:3 to about 3:1, polyvinyl acetate having GPC weight average molecular weight of about 2,000 to about 90,000, polyisoprene, polyethylene, vinyl acetate - vinyl laurate copolymer having vinyl laurate content of about 5% to about 50% by weight of the copolymer, and combinations thereof.
Preferred ranges for polyisobutylene are 50,000 to 80,000 GPC weight average molecular weight and for styrene-butadiene are 1:1 to 1:3 bound styrene-butadiene, for polyvinyl acetate are 10,000 to 65,000 GBC weight average molecular weight with the higher molecular weight polyvinyl acetates typically used in bubble gum base, and for vinyl acetate- vinyl laurate, vinyl laurate content of 10-45%.
Natural elastomers may include natural rubber such as smoked or liquid latex and guayule as well as natural gums such as jelutong, lechi caspi, perillo, sorva, massaranduba balata, massaranduba chocolate, nispero, rosindinha, chicle, gutta hang kang, and combinations thereof. The preferred synthetic elastomer and natural elastomer concentrations vary depending on whether the chewing gum in which the base is used is adhesive or conventional, bubble gum or regular gum, as discussed below. Preferred natural elastomers include jelutong, chicle, sorva and massaranduba balata. Elastomer plasticizers may include, but are not limited to, natural rosin esters such as glycerol esters or partially hydrogenated rosin, glycerol esters of polymerized rosin, glycerol esters of partially dimerized rosin, glycerol esters of rosin, pentaerythritol esters of partially hydrogenated rosin, methyl and partially hydrogenated methyl esters of rosin, pentaerythritol esters of rosin; synthetics such as teφene resins derived from alpha-pinene, beta-pinene, and/or d-limonene; and any suitable combinations of the foregoing. The preferred elastomer plasticizers will also vary depending on the specific application, and on the type of elastomer which is used.
Fillers/texturizers may include magnesium and calcium carbonate, ground limestone, silicate types such as magnesium and aluminum silicate, clay, alumina, talc, titanium oxide, mono-, di- and tri-calcium phosphate, cellulose polymers, such as wood, and combinations thereof.
Softeners/emulsifiers may include tallow, hydrogenated tallow, hydrogenated and partially hydrogenated vegetable oils, cocoa butter, glycerol monostearate, glycerol triacetate, lecithin, mono-, di- and triglycerides, acetylated monoglycerides, fatty acids (e.g. stearic, palmitic, oleic and linoleic acids), and combinations thereof. Colorants and whiteners may include FD&C-type dyes and lakes, fruit and vegetable extracts, titanium dioxide, and combinations thereof.
The base may or may not include wax. An example of a wax-free gum base is disclosed in U.S. Patent No. 5,286,500, the disclosure of which is incoφorated herein by reference. In addition to a water insoluble gum base portion, a typical chewing gum composition includes a water soluble bulk portion and one or more flavoring agents. The water soluble portion can include bulk sweeteners, high intensity sweeteners, flavoring agents, softeners, emulsifiers, colors, acidulants, fillers, antioxidants, and other components that provide desired attributes. Softeners are added to the chewing gum in order to optimize the chewability and mouth feel of the gum. The softeners, which are also known as plasticizers and plasticizing agents, generally constitute between approximately 0.5% to about 15% by weight of the chewing gum. The softeners may include glycerin, lecithin, and combinations thereof. Aqueous sweetener solutions such as those containing sorbitol, hydrogenated starch hydrolysates, corn syrup and combinations thereof, may also be used as softeners and binding agents in chewing gum.
Bulk sweeteners include both sugar and sugarless components. Bulk sweeteners typically constitute about 5% to about 95% by weight of the chewing gum, more typically, about 20% to about 80% by weight, and more commonly, about 30% to about 60% by weight of the gum. Sugar sweeteners generally include saccharide-containing components commonly known in the chewing gum art, including but not limited to, sucrose, dextrose, maltose, dextrin, dried invert sugar, fructose, levulose, glactose, corn syrup solids, and the like, alone or in combination. Sugarless sweeteners include, but are not limited to, sugar alcohols such as sorbitol, mannitol, xylitol, hydrogenated starch hydrolysates, maltitol, and the like, alone or in combination. High intensity artificial sweeteners can also be used, alone or in combination, with the above. Preferred sweeteners include, but are not limited to, sucralose, aspartame, salts of acesulfame, altitame, saccharin and its salts, cyclamic acid and its salts, glycerrhizinate, dihydrochalcones, thaumatin, monellin, and the like, alone or in combination. In order to provide longer lasting sweetness and flavor perception, it may be desirable to encapsulate or otherwise control the release of at least a portion of the artificial sweetener. Such techniques as wet granulation, wax granulation, spray drying, spray chilling, fluid bed coating, coacervation, and fiber extension may be used to achieve the desired release characteristics.
Combinations of sugar and/or sugarless sweeteners may be used in chewing gum. Additionally, the softener may also provide additional sweetness such as with aqueous sugar or alditol solutions.
If a low calorie gum is desired, a low caloric bulking agent can be used. Examples of low caloric bulking agents include: polydextrose; Raftilose, Raftilin; Fructooligosaccharides (NutraFlora); Palatinose oligosaccharide; Guar Gum Hydrolysate (Sun Fiber); or indigestible dextrin (Fibersol). However, other low calorie bulking agents can be used.
A variety of flavoring agents can also be used, if desired. The flavor can be used in amounts of about 0.1 to about 15 weight percent of the gum, and preferably, about 0.2%) to about 5% by weight. Flavoring agents may include essential oils, synthetic flavors or mixtures thereof including, but not limited to, oils derived from plants and fruits such as citrus oils, fruit essences, peppermint oil, spearmint oil, other mint oils, clove oil, oil of wintergreen, anise and the like. Artificial flavoring agents and components may also be used. Natural and artificial flavoring agents may be combined in any sensorially acceptable fashion. If the medicament or agent is water soluble in the chewing gum, it preferably will include a base/emulsifier system which leads to the desired concentration of the medicament in the saliva (more hydrophilic balance). If the medicament or agent is water insoluble, the chewing gum preferably includes a base/emulsifier system which leads to the desired concentration of the medicament in the saliva (more lipophilic balance). In manufacturing the chewing gum including the agent or ingredient, the agent or medicament is added, preferably, early on in the mix. The smaller the amount of active ingredient used, the more necessary it becomes to preblend that particular ingredient to assume uniform distribution throughout the batch of gum. Whether a preblend is used or not, in a preferred embodiment, the agent or medicament should be added within the first five minutes of mixing.
By way of example, and not limitation, examples of some chewing gum formulations including a medicament or agent are as follows:
ASPIRIN GUM
INGREDIENT PERCENTAGE
Sugar 48.44
Gum Base 19.50
Corn Syrap 10.00
Glycerine 3.00
Aspirin 12.04
Caffeine 1.19
Artificial Flavors 0.90
Aspartame 0.23
Fructose 4.50
Soluble Saccharin 0.16
Insoluble Saccharin 0.04
100.00
2.7g stick yields 325 mg aspirin and 32 mg caffeine FORMULA AVAILABLE EXCLUDING CAFFEINE CAFFEINE GUM
INGREDIENT PERCENTAGE
Sugar 56.54
Gum Base 19.80
5 Corn Syrap 8.20
Natural & Artificial Flavors 3.60
Glycerine 3.00
Xylitol 2.90
Dextrose 2.30
10 Caffeine 1.80
Low Fat Cocoa 1.00
Lecithin 0.50
Aspartame 0.29
Acesulfame-K 0.05
15 BHT 0.02 100.00
ACETAMINOPHEN GUM
INGREDIENT PERCENTAGE
Sugar 54.77
20 Gum Base 21.80
Corn Syrap 11.20
Fructose 5.60
Glycerine 3.40
Acetaminophen 1.70
25 Flavors 1.00
Aspartame 0.26
Soluble Saccharin 0.21
Insoluble Saccharin 0.06
100.00 30 *5 gram chunk yields 85 mg acetaminophen
Formula can be modified to include caffeine. By way of example, and not limitation, examples testing the chewing gum formulation of the present invention are as follows:
Experiment No. 1 Single dose, placebo controlled, randomized, two-way crossover study in 20 subjects to evaluate the effect of 50 mg caffeine gum compared to placebo gum-on positive and negative mood affects. Healthy subjects 18-65. Screening questionnaire to evaluate average caffeine consumption, tobacco drag and alcohol status. Any subjects taking medications with a CNS affect were excluded from the study. Approximately 2 hours on two occasions separated by at least 24 hours. Dosing: 1 x stick of caffeine gum to be chewed for 30 minutes. The chewing gum had the formulation set forth above in the table entitled caffeine gum.
The subjects were instructed that they were to have caffeine, alcohol or other drug use for at least 8 hours prior to test. No tobacco products for at least 2 hours prior to test. Subjects must have been awake and active for at least 8 but no more than 16 hours prior to starting the test. Subjects will be required to complete a 10 part questionnaire at the following time points (-20, -10, -5 and at 2, 5, 10, 15, 20, 30, 40 and 1 hour after starting to chew the gum. Appropriate analysis of comparison of each individual item of the test and grouped analysis for both positive and negative affect.
Data was corrected for baseline data (-5 minute reading) at each time point. Means and standard deviations for both active and placebo groups were evaluated for all time points.
The results of the analysis are set forth in Figure 1. Figure 1 graphically illustrates alertness versus time. These results demonstrate that by 5 minutes the subject reported that they were quite a bit alert. The alertness response was based on reference Panas feeling and emotion scale.
Experiment No. 2
A randomized, single-dose, two-way crossover study was conducted with six (6) healthy, adult, non-tobacco-using male subjects. A single 100 mg does of caffeine was administered in each study period after an overnight fast. The test treatment was two 50mg caffeine chewing gum pieces (sticks), which were chewed for 15 minutes and removed. The reference treatment was one 1 OOmg chewable No-Doz® tablet, which was chewed and swallowed. One of the treatments was given in each period; the order of administration was according to the dosing randomization schedule. There was a 7-day washout between treatments.
Blood samples were collected pre-dose and over 15 hours after each dose. Plasma concentrations of caffeine were measured by a fully validated chromatographic procedure. Samples from subject with measurable pre-dose levels of caffeine were corrected for these levels. Pharmacokinetic parameters were calculated from the adjusted data and statistical analyses were performed to compare the test and reference treatments.
Clinical Procedures
A. Subject Selection.
The 6 subjects who participated in this study were healthy males, in the age range of 25 to 35 years, and within 15% of their ideal weight as specified in the protocol.
All subjects were selected based on the absence of any clinically significant findings on the medical history, physical examination, and clinical laboratory evaluations. Any laboratory value or vital sign measurement more than 10% outside the normal range was evaluated individually by the investigator. All were determined to be not clinically significant for those subjects enrolled in the study. All screening evaluations were performed within 28 days of initial dosing. B. Drag Supplies.
Formulations: Test (A) - Two 50mg chewing gum sticks, Amurol Confections Co.
(Lot #ALRT7/9/19/96, No exp. Date) Reference (B) - One lOOmg No-Doz® chewable table, Bristo-Myers Products (Lot #601041, Exp. date 10/98).
Admimsfration: The subjects received the test and reference after an overnight fast. The subjects randomized to the test first drank 240 ml of room temperature tap water. The chewing gum pieces were then chewed for 15 minutes and deposited into a labeled vial. The subjects randomized to the reference chewed the No-Doz® tablets and then drank 240 ml of room temperature tap water. The order of treatment administration was according to the randomization schedule. All doses were administered at one-minute intervals beginning at 0700 hours. A thorough mouth check was performed to ensure that the chewable tablet was swallowed.
A schedule of the actual dosing times, dates and treatment assignments is included in
Table C2. All subjects remained under observation sitting upright or standing for at least two hours after each dosing. Six subjects were dosed in both Period I and Period II.
C. Study Conduct.
Confinement, Meals: During the confinement periods of this study, the subjects were housed and fed at the clinical facility.
In each period, the subjects reported for check-in (Day -1) at least 12 hours before dosing. Meals were provided on check-in day and completed at least 10 hours prior to scheduled dosing time. No food or beverages (except water) were permitted after 2100 hours on Day -1.
During confinement (Day 1), standardized, caffeine-free meals or snacks were served at 4, 10 and 14 hours after dosing, as specified on the Activity Schedule and Menu found in Section 3. The same menu was used during each study period. The subjects consumed at least 95% all food and beverages that were required. The subjects were released from the clinical facility approximately 2200 hours after dosing in each study period. A 7-day washout separated the dosings.
Restrictions: Prior to check-in for the study, the subjects were instructed to take no prescribed medications for at least 14 days prior to the initial dosing and throughout the study. No over-the-counter medications were permitted for 72 hours before dosing in each study period. No medications were permitted during confinement except those administered. Subjects were also instructed to abstain from any products containing alcohol or caffeine for 48 hours prior to dosing and throughout each confinement. None of the subjects reported taking any restricted substance within the time frame indicated.
During the confinement periods of the study, water was restricted from one hour before until one hour after dosing except for water (240 ml) administered with the dose.
Water was permitted ad lib at all other times. Subjects remained sitting upright or standing for 2 hours after each dosing, except as required for study procedures. No strenuous physical exercise was permitted during confinement.
Safety: Urine drag screens were performed at each check-in to test for alcohol, marijuana and cocaine metabolites.
Blood pressure (sitting), pulse rate, respiratory rate and oral temperature were measured before each dosing. The investigator considered the measurements of all subjects as clinically acceptable for dosing. Blood pressure and pulse rate measurements (sitting) were obtained approximately one hour after each dose and prior to release in each study period to monitor the health of the subjects. Measurements were repeated if clinically warranted.
A blood sample was collected at the time of the last sample of the study for a hematocrit determination. All hematocrit values were within 10% of the normal range (41-50%).
Adverse Events: The subjects were monitored throughout the study for any adverse experiences. They were encouraged to report signs, symptoms, and any changes in health to the study nurse. None of the subject reported any adverse events during this study. Pharmacokinetic Samples: In each period, blood samples were collected prior to dosing and at the following nominal times after dosing: 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 and 15 hours. The samples were labeled at the time of collection with a unique 6-digit code number. Pre-dose samples were collected within 30 minutes before dosing. All plasma samples were stored frozen between -18°C and -20°C until transfer to the laboratory for analysis, with the exception of one day.
Subject Completion: A total of 6 subjects were entered into the study and all subjects completed one study. Analytical Procedures
A. Quality Control. Standards and Controls: Calibration standards were prepared spiking a pool of human, interference-free, heparinized plasma with caffeine (USP Reference, Lot I). The plasma was obtained from Interstate Blood Bank (Memphis, TN). The standards were prepared to contain 0.050, 0.100, 0.200, 0.500, 1.00, 2.00 and 5.00 μg/ml of caffeine. The caffeine standards and controls were divided into 2.5ml aliquots and stored in the laboratory in polypropylene snap-cap tubes frozen to at least -19°C. The pre-study within-run coefficient of variation ranged from 0.915% to 2.54%. The relative accuracy of the procedure was estimated, through comparison of the measured concentration means of the control samples against their theoretical concentrations, and was found to average 99.5% for caffeine. Run Acceptance Criteria: Chromatographic peak responses and peak response ratios were monitored using an electronic integrator. Each chromatographic tracing was inspected for acceptable retention times, peak shapes, resolution and integration before the peak response ratios (analyte-to-internal standard) were entered into the computer. The acceptable limit of quantization for the ran was evaluated through comparison of the mean response of the lowest concentration standards (0.050 g/ml) with the responses of any interferences observed in the water blank, matrix blank and zero standard. The limit of quantization for the ran was defined as the concentration at which the signal-to-noise ratio was at least 2.
Samples, standards and controls with an internal standard peak response which deviated more than ±25% from the mean within-run peak response of the internal standard (calculated for all standards and controls) were rejected.
The response ratio for each remaining non-zero standard was plotted as a function of concentration. A linear regression was calculated (R/S 1, version 4.3) by the method of least- squares using (1/CONC)2 as a weighting factor. With this calibration line, a calculated concentration was determined for each standard sample. Any standard differing by more than ±25%) from its theoretical value was excluded from the regression and the regression was recalculated. The analyte concentrations in the samples and the controls were estimated from the calibration line by use of the equation: (RATIO - LNTERCEPT)/SLOPE. The analytical run was considered acceptable if 4 of 6 controls passed established acceptance criteria and that at least one control sample was acceptable within each concentration range. Controls within an analytical run were considered acceptable if the low control values differed by no more than ±20% and the middle and high controls differed by no more than ±15% from their theoretical values. The concentrations o the controls were graphically displayed to permit visual confirmation of acceptability and identification of trends. B. Sample Analysis.
Sample Storage and Stability: The plasma samples, which were collected in the clinic were transferred to the laboratory and stored frozen to at least -19°C until analyzed. Samples were not identified to the analysts by treatment group. All subjects' samples were analyzed within 19 days of the initial sampling. The frozen stability of caffeine in plasma has been confirmed for 138 days.
Peak Identification: The retention times of the analyte and the internal standard were identified, in any given analytical run, by comparison to stock standards chromatographed at the beginning of the run and to processed standards chromatographed through the run.
Pharmacokinetic and Statistical Procedures
A. Pharmacokinetic Data.
All the available data from 6 subjects with reported caffeine concentrations were used in the pharmacokinetic analyses. Several subjects had pre-dose samples which contained measurable concentrations of caffeine. For each of these subject's data, the measured concentration at each sampling time was corrected by subtracting the level of caffeine at that time predicted from the decay of the pre-dose level. The decay curve was constructed using the elimination rate observed in the same period as the decay constant. After adjustment, each pre-dose level was 0.0 μg/ml, and each post-dose concentration was reduced accordingly.
Pharmacokinetic parameters (areas, times to peak, and elimination rates and half- lives) were calculated using the actual rather than the scheduled time of sample collection. Graphical presentations of individual subject results also used the exact times of sample collection. Graphical presentations of mean results used the scheduled times of sample collection.
Peak concentration (Cmax) was the observed maximum value (corrected for pre- dose levels, if necessary) during the collection period of 0 to 15 hours. The time to peak concentration (Tmax) was the time at which Cmax was observed (or first observed, if more than one peak was present). The apparent first-order elimination rate (Ke) was estimated as the absolute value of the slope of the regression line for the terminal log- linear concentration- time values. The values included in the regression analyses were determined by examination of the individual subject plots of natural logarithm of concentration against time. Elimination half-life (t-'/i) was calculated as 0.693/Ke.
Area under the curve (AUC) to the time of the last non-zero concentration (C,) was calculated by the linear trapezoidal method. Area to infinite time (AUCinf) was calculated by extrapolating AUC by the addition of the quantity: C Ke. B. Statistical Analyses.
Statistical analyses were performed using the General Linear Models (GLM) procedures of the SAS statistical program. Hypothesis testing for treatment effects was conducted at α=0.05. The statistical model contained main effects of sequence, subject within sequence, period, and treatment. Sequence effects were tested against the type HI mean square term for subjects within sequence. All other main effects were tested against the mean square error term.
The observed and calculated pharmacokinetic parameters as well as the caffeine concentrations at each of the individual collection times were compared statistically.
Power for the pair-wise pharmacokinetic comparisons was calculated as the probability (α=0.05) of detecting a difference equal to 20% of the mean for the reference treatment in the comparison, or a ratio of 1.25 for In-transformed results. [Winer, BJ.
Statistical Principles In Experimental Design. NEW YORK: McGraw-Hill Book Company (1962) 21-26.]
Confidence Intervals (90%) for pair-wise area and peak concentrations comparisons were calculated by the t-test approach (2,1 -sided) at α=0.05 each side. The intervals were computed for the "true" mean test-to-reference treatment ratio (or geometric mean ratio for In-transformed results). Discussion and Results
Statistical analyses were performed on the caffeine data in order to compare the test chewing gum to the chewable reference tables. Natural log-transformation of the area and Cmax parameters was also performed and analyzed statistically. Table 1, which follows, summarizes the results (n=6) of the statistical analyses of the major bioavailability parameters. Statistical comparisons of the test and reference formulations at each sampling time are summarized in Table 2. Conclusion
The caffeine chewing gum pieces appear to have a much faster rate of absoφtion that the No-Doz® chewable tablets. The areas and peak concentrations of the chewing gum were less than half that of No-Doz®, and the time to reach a peak for the gum was
30 minutes earlier than for the tablet.
Table 1 : Comparisons of caffeine results for 50mg chewing gum pieces (Test) vs. lOOmg No-Doz® chewable tablets (Reference) administered as a single lOOmg dose under fasting conditions to 6 subjects.
Parameter Least Squares Means' Test/Ref. Power3 90% Confidence Interval4
Test Reference Ratio2 Lower Upper
AUC 0-t 7.26 17.65 0.412* 0.50 0.246 0.577
(μg-hr/ml)
AUCinf 9.60 23.72 0.405* 0.39 0.211 0.598 (μg-hr/ml)
Cmax 0.92 2.15 0.429* 0.76 0.309 0.548
( g/ml)
Tmax 1.08 1.58 0.684 0.22
(hour)
Ke 0.1241 0.1058 1.173* 0.86
(1/hour)
Elimhalf 5.97 6.97 0.857* 0.86
(hour)
Ln-Transformed Data
AUC 0-t 6.22 17.44 0.357* 0.15 0.239 0.532
(μg-hr/ml)
AUCinf 7.66 23.00 0.333* 0.13 0.212 0.524 (μg-hr/ml)
Cmax 0.84 2.14 0.391* 0.17 0.272 0.562
(μg/ml)
1 Least squares geometric means for In-transformed data.
2 Test Ref Ratio calculated as Test mean divided by Reference mean. 3 Power to detect a difference of 20% (original data) or a ratio of 1.25 (In- transformed data).
4 Confidence interval on the ratio. * Detected as statistically significant by ANOVA ( =0.05). Table 2: Summary of caffeine statistical comparisons at each sampling time comparing 50mg chewing gum pieces (Test) vs. lOOmg No-Doz® chewable tablets (Reference) administered as a single lOOmg dose under fasting conditions to 6 subjects.
Sample Collection Least Squares Means ( g/ml) Significance
Time (Hour) Test Reference *
I Pre-dose 0.00 0.00
2 0.25 0.23 0.36 0.0269
3 0.50 0.79 1.18 None
4 1.00 0.83 1.91 0.0008
5 1.50 0.84 2.05 0.0006
6 2.00 0.75 2.01 0.0004
7 2.50 0.72 1.92 0.0001
8 3.00 0.68 1.78 . 0.0006
9 4.00 0.66 1.64 0.0006
10 6.00 0.57 1.33 0.0046
11 8.00 0.47 1.10 0.0088
12 10.00 0.37 0.90 0.0052
13 12.00 0.28 0.75 0.0021
14 15.00 0.22 0.56 0.0068
Statistical comparisons to test for the equivalence of treatment effects were performed at an a level of 0.05. The actual p- value is indicated at the time where statistically significant differences (pθ.05) were detected; "None" indicates that no significance was detected (p<0.05) at that time.
Figure 2 illustrates graphically least squares mean plasma concentration (~=6)- Concentration of caffeine in (reg ml) versus hours of the dose is illustrated graphically; chewing gum provided 50mg of caffeine versus lOOmg of No-Doz® tablet. It should be noted that although in Figure 2 the blood concentration level of caffeine is approximately 50% that of No-Doz®, the amount of caffeine delivered by the chewing gum was 50% that of the No-Doz®. Experiment No. 3
The following protocol was followed. The chewing gum formula set forth on page 15 under the heading caffeine gum was used. Subjects chewed gum for 5 minutes. Then, the gum cuds were then collected and analyzed for caffeine. At T-10 minutes, the gum was collected after chewing for 10 minutes and then had the caffeine analyzed. This was repeated for all the time figures up to time 60 minutes. "Times 0" refers to non- chewed gum product. All these T-0 to T-60 minute gum samples were from the same lot of chewing gum.
The results are as follows:
Figure 3 illustrates graphically % caffeine remaining over chew-out time in minutes.
Experiment No. 4
To detect adsoφtion in the oral cavity, the following experiment was carried out. Samples of Stay- Alert Cinnamon flavored caffeine gum (Lot 713176) were analyzed for caffeine and found to contain 53.44±0.52 mg per stick. Two subject (SI and S2) were recruited to chew the gum. Each subject chewed one stick of gum for 20 minutes, expectorating all saliva into a container. After chewing, each rinsed twice with 10 ml of water (20 ml total) and added the rinse water to the collected saliva. The volume of this solution was brought up to 75 ml with distilled water. S2 repeated the extraction process with a new stick of gum. The chewed gum cuds and the saliva solutions were analyzed for caffeine by gas chromatography. (A spiking study was also conducted which showed recovery of caffeine from gum cuds and saliva solutions to be 99.25% and 103.50% respectively. Measured caffeine levels were not corrected for these recoveries as they were not deemed significantly different from 100%.) The results of the experiment are reported in Table 4.
Figure imgf000027_0001
It is believed that the unrecovered caffeine was adsorbed through mucous membranes in the oral cavity. Thus between 11 and 25% of the released caffeine was adsorbed orally. Note that the higher concentration of caffeine in saliva for S2 may have contributed to the higher adsoφtion in that subject.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

Claims

WE CLAIM:
1. A method for delivering a medicament to an individual comprising the steps of: providing a chewing gum that includes a medicament in the chewing gum composition; chewing the chewing gum to cause the medicament to be released from the chewing gum composition into the buccal cavity of the individual; and continuing to chew the chewing gum thereby creating a fluid pressure causing the medicament to enter the systemic system of the individual through an oral mucosa of the individual.
2. The method of Claim 1 wherein the chewing gum is chewed for at least 2 minutes.
3. The method of Claim 1 wherein the chewing gum creates a saliva content of medicament of approximately 1700 to about 4400 ppm.
4. The method of Claim 1 wherein the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antibiotics; antivirals; antihistamines; decongestants; anti-inflammatories; antacids; psychotherapeutic agents; insulin; vitamins; minerals; and cardiovascular agents.
5. The method of Claim 1 including the steps of chewing a chewing gum including the medicament at least twice a day.
6. The method of Claim 1 wherein the chewing gum creates a saliva content of medicament of approximately 4 ppm to about 450 ppm.
7. A method for reducing the amount of agent necessary to achieve an effect in an individual as compared a typical agent that is swallowed comprising the steps of: providing a chewing gum including an agent that is typically swallowed by an individual to achieve a specific effect, the chewing gum including less than the typical amount of agent that is swallowed by the individual to achieve the effect; chewing the chewing gum and thereby causing the agent to be released into the salvia of the individual; and continuing to chew the chewing gum forcing the agent through an oral mucosa contained in a buccal cavity of the individual.
8. The method of Claim 7 wherein the agent is a medicament.
9. The method of Claim 8 wherein the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antibiotics; antivirals; antihistamines; decongestants; anti-inflammatories; antacids; psychotherapeutic agents; and cardiovascular agents.
10. The method of Claim 7 wherein the chewing gum is chewed for at least 2 minutes.
11. The method of Claim 7 wherein the chewing gum creates a saliva content of medicament of approximately 15 to about 440 ppm.
12. The method of Claim 7 including the steps of chewing a chewing gum including the medicament at least twice a day.
13. The method of Claim 7 wherein the agent is a stimulant.
14. A method of enhancing an individual's performance comprising the steps of: providing a chewing gum including a performance enhancing amount of caffeine; and chewing the chewing gum not more than ten minutes before the performance.
15. The method of Claim 14 wherein the performance to be enhanced is athletic.
16. The method of Claim 14 wherein the performance to be enhanced is cognitive.
17. The method of Claim 14 wherein the performance to be enhanced is alertness.
18. The method of Claim 14 wherein the chewing gum is chewed five minutes or less before the performance.
19. A method of delivering a medicament comprising the steps of: providing a chewing gum including a medicament; and chewing the chewing gum for at least 2 minutes in a buccal cavity of an individual chewing the chewing gum.
20. The method of Claim 19 wherein the medicament is chosen from the group consisting of: analgesics; muscle relaxants; antibiotics; antivirals; antihistamines; decongestants; anti-inflammatories; antacids; psychotherapeutic agents; and cardiovascular agents.
21. The method of Claim 19 including the steps of chewing a chewing gum including the medicament at least twice a day.
22. The method of Claim 19 wherein two pieces of chewing gum are chewed at a time.
23. A method of increasing the stimulatory effect of a stimulant that has been previously swallowed by an individual comprising the steps of: providing a chewing gum that contains the stimulant; and chewing the chewing gum causing the stimulant to be released by the chewing gum and forced into an oral mucosa located in a buccal cavity of the individual.
24. The method of Claim 23 wherein the stimulant is caffeine.
25. The method of Claim 23 wherein the chewing gum creates a saliva content of medicament of approximately 15 to about 440 ppm.
PCT/US2000/007991 1999-04-06 2000-03-24 Pharmaceutical chewing gum formulations WO2001021156A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00919655A EP1181010A4 (en) 1999-04-06 2000-03-24 Pharmaceutical chewing gum formulations
AU40308/00A AU784112B2 (en) 1999-04-06 2000-03-24 Pharmaceutical chewing gum formulations
JP2001524582A JP2003509455A (en) 1999-04-06 2000-03-24 Pharmaceutical chewing gum formulation
CA002369515A CA2369515A1 (en) 1999-04-06 2000-03-24 Pharmaceutical chewing gum formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28681899A 1999-04-06 1999-04-06
US09/286,818 2000-02-23

Publications (1)

Publication Number Publication Date
WO2001021156A1 true WO2001021156A1 (en) 2001-03-29

Family

ID=23100292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007991 WO2001021156A1 (en) 1999-04-06 2000-03-24 Pharmaceutical chewing gum formulations

Country Status (7)

Country Link
US (1) US7078052B2 (en)
EP (1) EP1181010A4 (en)
JP (1) JP2003509455A (en)
AU (1) AU784112B2 (en)
CA (1) CA2369515A1 (en)
RU (2) RU2219912C2 (en)
WO (1) WO2001021156A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003235472A (en) * 2002-02-14 2003-08-26 Wm Wrighley Jr Co Coating product containing reduced indigestive millet jelly as binder component
WO2006073356A1 (en) * 2005-01-04 2006-07-13 Peter Stigsson An arrangement for inserting caffein into a mouth cavity
WO2006090388A2 (en) 2005-02-25 2006-08-31 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Fruit cell culture extract for treating inflammation
DE102008057257A1 (en) 2008-11-13 2010-05-20 Eucro European Contract Research Gmbh & Co. Kg Collecting oral mucosal cells and/or -cell fragments from patients, comprises allowing patient to chew a water-insoluble, indigestible chewing mass, during which cells are absorbed in chewing mass and separating the cells from chewing mass
WO2010054639A2 (en) 2008-11-13 2010-05-20 Eucro European Contract Research Gmbh & Co. Kg Method for collecting oral mucosa skin cells and/or cell fragments
DE102009016075A1 (en) 2009-04-03 2010-10-07 Eucro European Contract Research Gmbh & Co. Kg Collecting oral mucosa cells and/or cell fragments from patients, comprises chewing water insoluble, non-digestible chewing mass by the patient, adsorbing oral mucosa skin cells, DNA, RNA/their fragments by chewing mass and separating

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589489C (en) 2004-11-30 2014-04-22 Fertin Pharma A/S Method of providing fast relief to a user of a nicotine chewing gum
US8323683B2 (en) * 2005-05-18 2012-12-04 Mcneil-Ppc, Inc. Flavoring of drug-containing chewing gums
US20070003490A1 (en) * 2005-06-29 2007-01-04 Medical Futures Inc. Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against NSAID gastropathy
CA2661581C (en) * 2006-09-27 2014-09-23 Cadbury Adams Usa Llc Cooling confectioneries and beverages
EP2217266A2 (en) * 2007-11-06 2010-08-18 Kristian Hellgren A method for treating ailments of the oral cavity with a krill enzyme composition
WO2009065102A1 (en) * 2007-11-16 2009-05-22 Cadbury Adams Usa Llc Confectionery compositions including markings for delivery of actives
US20110038915A1 (en) * 2009-08-14 2011-02-17 Eduardo Jose Gonzalez Chewing Gum Formula for Enhancing Psycho-Spirituality
GB2478931B (en) * 2010-03-23 2013-06-12 John Paul Kelly Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity
JP2011057701A (en) * 2010-12-09 2011-03-24 Fertin Pharma As Method to give rapid alleviation for nicotine chewing gum user
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US10441535B2 (en) * 2014-12-29 2019-10-15 NeuroGum, LLC Nutraceutical confectionary composition containing caffeine and L-theanine
USD796775S1 (en) 2015-09-09 2017-09-12 Intercontinental Great Brands Llc Confection
RU2674944C1 (en) * 2018-01-24 2018-12-13 Павел Павлович Хорошутин Method for provision of remote psychological assistance
WO2020167325A1 (en) * 2019-02-11 2020-08-20 Ruschhaupt Ryan Blood alcohol concentration indicator chewing gum

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013716A (en) * 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1298670A (en) * 1915-06-11 1919-04-01 Stuart W Cramer Chewing-gum.
GB934596A (en) 1961-05-08 1963-08-21 Warner Lambert Pharmaceutical Chewing gum
GB963518A (en) 1962-07-31 1964-07-08 Warner Lambert Pharmaceutical Slab chewing gum
DE1216486B (en) * 1964-04-23 1966-05-12 Merck Ag E Process for the production of coated tablets
FR2262005B1 (en) 1974-02-22 1978-01-06 Raffinage Cie Francaise
US3995064A (en) * 1975-06-04 1976-11-30 Life Savers, Inc. Method and apparatus for forming chewing gum base and product
US4238510A (en) * 1979-02-21 1980-12-09 Life Savers, Inc. Sugarless coating for chewing gum and confections and method
JPS6056143B2 (en) * 1979-08-02 1985-12-09 山之内製薬株式会社 Amidine derivatives and their production method
US4238475A (en) * 1979-08-01 1980-12-09 Life Savers Inc. Chewing cum capable of releasing finely divided water-insoluble materials therefrom
US4250195A (en) * 1979-09-24 1981-02-10 Life Savers, Inc. Method for applying soft flexible sugar coating to fresh chewing gum and coated chewing gum product
US4317838A (en) * 1979-09-24 1982-03-02 Life Savers, Inc. Method for applying sugarless coating to chewing gum and confections
US4374858A (en) * 1979-10-04 1983-02-22 Warner-Lambert Company Aspartame sweetened chewing gum of improved sweetness stability
US4386106A (en) * 1981-12-01 1983-05-31 Borden, Inc. Process for preparing a time delayed release flavorant and an improved flavored chewing gum composition
US4378374A (en) * 1981-12-21 1983-03-29 Nabisco Brands, Inc. Chewing gum having improved softness
US4446135A (en) * 1982-06-07 1984-05-01 Sterling Drug Inc. Chewable antacid tablets
US4459311A (en) * 1983-01-03 1984-07-10 Nabisco Brands, Inc. Process for preparing gum base
US4555407A (en) * 1984-12-24 1985-11-26 General Foods Corporation Continuous chewing gum method
JPS61242561A (en) 1985-04-22 1986-10-28 Nippon Chem Ind Co Ltd:The Food additive
ZA867327B (en) 1985-11-04 1987-05-27 Warner Lambert Co Flavored tableted chewing gum
US4882152A (en) * 1985-12-20 1989-11-21 Yang Robert K Confectionery delivery system for laxatives, vitamins and antacids
FR2607671B1 (en) 1986-12-04 1991-02-08 Gen Foods France PROCESS FOR THE DIRECT MANUFACTURE OF BASE GUM FOR MASTICATORY PASTE AND CHEWING GUM
FR2635441B1 (en) 1988-08-18 1991-12-27 Gen Foods France HIGH POLYMER BASE GUM BASE CONCENTRATES, THEIR PREPARATION PROCESS AND THEIR USE IN THE MANUFACTURE OF CHEWING GUM
US5110608A (en) * 1988-12-29 1992-05-05 Warner-Lambert Company Chewing gums having longer lasting sweetness
US4968511A (en) * 1989-03-10 1990-11-06 Amelia Ronald P D Composition and process for one-step chewing gum
US5139794A (en) * 1989-04-19 1992-08-18 Wm. Wrigley Jr. Company Use of encapsulated salts in chewing gum
JP2863586B2 (en) 1990-02-27 1999-03-03 株式会社ロッテ Chewing gum
US5045325A (en) * 1990-09-26 1991-09-03 Warner-Lambert Company Continuous production of chewing gum using corotating twin screw extruder
US5244670A (en) * 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
US5629013A (en) * 1991-04-04 1997-05-13 The Procter & Gamble Company Chewable calcium carbonate antacid tablet compositions
RU2029474C1 (en) 1991-06-28 1995-02-27 Тетюшева Светлана Игоревна Chewing gum
EP0661966B1 (en) * 1991-12-17 2000-07-19 Biovail Technologies Ltd. Ulcer prevention and treatment composition and method
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
US5286500A (en) * 1992-03-03 1994-02-15 Wm. Wrigley Jr. Company Wax-free chewing gum base
US5665406A (en) * 1992-03-23 1997-09-09 Wm. Wrigley Jr. Company Polyol coated chewing gum having improved shelf life and method of making
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
US5256995A (en) 1992-07-17 1993-10-26 Ball Corporation Low helium permeability atomic frequency standard cell and method for forming same
JPH06303911A (en) 1993-04-16 1994-11-01 Kanebo Ltd Production of chewing gum
ZA944294B (en) 1993-06-23 1995-02-13 Nabisco Inc Chewing gum containing hydrophobic flavorant encapsulated in a hydrophilic shell
CN1125902A (en) 1993-06-23 1996-07-03 Wm.雷格利Jr.公司 Improved chewing gum and candy products
US5543160A (en) * 1994-09-13 1996-08-06 Wm. Wrigley Jr. Company Total chewing gum manufacture using high efficiency continuous mixing
US5419919A (en) * 1993-10-22 1995-05-30 Wm. Wrigley Jr. Company Continuous gum base manufacture using paddle mixing
US5397580A (en) * 1993-10-22 1995-03-14 Wm. Wrigley Jr. Company Continuous gum base manufacture using sequential mixers
ES2233932T3 (en) 1993-10-13 2005-06-16 Warner-Lambert Company Llc PHARMACEUTICAL COMPOSITION OF ANTIACIDO.
DE4342568A1 (en) 1993-12-14 1994-06-01 Paul Ralf Peter Chewing gum contg. caffeine - used as substitute for coffee, tea, cola, etc. and to control fatigue and migraine
US5834002A (en) * 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US5536511A (en) * 1994-05-06 1996-07-16 Wm. Wrigley Jr. Company Chewing gum pellet coated with a hard coating containing erythritol and xylitol
DE4415999A1 (en) * 1994-05-06 1995-11-09 Bolder Arzneimittel Gmbh Gastric acid-binding chewing pastilles
EP0824870A3 (en) * 1994-06-03 1999-03-31 Asama Chemical Co., Ltd. Wheat gluten fractions
MA23587A1 (en) 1994-06-23 1995-12-31 Procter & Gamble TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME
JPH0819370A (en) 1994-07-06 1996-01-23 Masaya Nagai Production of after meal chewing gum
US5576344A (en) * 1994-08-30 1996-11-19 American Home Products Corporation Process for reducing the adverse taste and malodor associated with H2 -antagonists
CA2199608C (en) * 1994-09-13 2001-10-23 Joo Song Method for continuous gum base manufacturing
US5601858A (en) * 1994-12-29 1997-02-11 Warner-Lambert Company Non-stick chewing gum
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5569477A (en) * 1995-04-28 1996-10-29 Mccready Consumer Products, Inc. Chewing gum containing vitamins or other active materials
US5854267A (en) * 1995-06-02 1998-12-29 Merck & Co., Inc. Method for preventing heartburn
DE19529862A1 (en) * 1995-08-14 1997-02-20 Rhone Poulenc Rorer Gmbh Pharmaceutical preparation for oral use
EP0867191A4 (en) * 1995-11-27 2000-01-05 Yamanouchi Pharma Co Ltd Drug composition
GB9525240D0 (en) 1995-12-09 1996-02-07 Glaxo Wellcome Lab Sa Ranitidine compositions
US6066342A (en) * 1995-12-22 2000-05-23 Tamer International, Ltd. Antacid composition
GB9526636D0 (en) 1995-12-29 1996-02-28 Procter & Gamble Chewable compositions
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
DE19639342C2 (en) 1996-09-25 1998-07-16 Suedzucker Ag Chewing gum containing a sweetener
US5989588A (en) * 1996-10-04 1999-11-23 Merck & Co., Inc. Methods and compositions for preventing and treating heartburn
EP0969733B1 (en) * 1996-11-27 2006-06-21 Wm. Wrigley Jr. Company Method of controlling release of caffeine in chewing gum and gum produced thereby
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
US6165516A (en) * 1996-11-27 2000-12-26 Wm. Wrigley Jr. Company Method of controlling release of caffeine in chewing gum
US5980955A (en) * 1996-12-30 1999-11-09 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6242018B1 (en) * 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
US5858383A (en) * 1997-08-11 1999-01-12 Summers Laboratories, Inc. Methods and compositions for topical treatment of ectoparasites
AU5595498A (en) 1997-12-03 1999-06-16 Wm. Wrigley Jr. Company Improved chewing gum formulations including aspartame and sodium bicarbonate
DE69921972T2 (en) 1998-03-04 2005-12-01 Dandy A/S Coated chewing gum, method for producing and using one or more solid active substances
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6024988A (en) * 1998-06-01 2000-02-15 Wm. Wrigley Jr. Company Caffeine chewing gum
AU5476599A (en) 1998-09-08 2000-03-27 Biovail International Ltd. Encapsulation of caffeine
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6586023B1 (en) * 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6627234B1 (en) * 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
CA2357923C (en) 1998-12-30 2005-03-15 David G. Barkalow Coating process applying powder and suspension syrup
US6355265B1 (en) * 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6322806B1 (en) * 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6429198B1 (en) * 1999-04-12 2002-08-06 Bioenergy Inc. Compositions for increasing athletic performance in mammals
US6413558B1 (en) * 1999-07-19 2002-07-02 The Proctor & Gamble Co. Compositions, kits, and methods for providing and maintaining energy and metal alertness
US6663849B1 (en) * 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6569472B1 (en) * 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6541048B2 (en) * 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US6645535B2 (en) * 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6350480B1 (en) * 1999-12-30 2002-02-26 Wm. Wrigley Jr. Company Chewing gum product including a hydrophilic gum base and method of producing
US6572900B1 (en) * 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US6444241B1 (en) * 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) * 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
US6613346B2 (en) * 2001-06-28 2003-09-02 Wm. Wrigley, Jr. Company Chewable product including active ingredient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013716A (en) * 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003235472A (en) * 2002-02-14 2003-08-26 Wm Wrighley Jr Co Coating product containing reduced indigestive millet jelly as binder component
US8114421B2 (en) 2002-02-14 2012-02-14 Wm Wrigley Jr. Company Coated products containing hydrogenated indigestible starch syrup as a binding agent
WO2006073356A1 (en) * 2005-01-04 2006-07-13 Peter Stigsson An arrangement for inserting caffein into a mouth cavity
WO2006090388A2 (en) 2005-02-25 2006-08-31 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Fruit cell culture extract for treating inflammation
US8216801B2 (en) 2005-02-25 2012-07-10 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), The Volcani Center Methods for treating inflammatory disorders
DE102008057257A1 (en) 2008-11-13 2010-05-20 Eucro European Contract Research Gmbh & Co. Kg Collecting oral mucosal cells and/or -cell fragments from patients, comprises allowing patient to chew a water-insoluble, indigestible chewing mass, during which cells are absorbed in chewing mass and separating the cells from chewing mass
WO2010054639A2 (en) 2008-11-13 2010-05-20 Eucro European Contract Research Gmbh & Co. Kg Method for collecting oral mucosa skin cells and/or cell fragments
DE102009016075A1 (en) 2009-04-03 2010-10-07 Eucro European Contract Research Gmbh & Co. Kg Collecting oral mucosa cells and/or cell fragments from patients, comprises chewing water insoluble, non-digestible chewing mass by the patient, adsorbing oral mucosa skin cells, DNA, RNA/their fragments by chewing mass and separating

Also Published As

Publication number Publication date
AU784112B2 (en) 2006-02-09
CA2369515A1 (en) 2001-03-29
JP2003509455A (en) 2003-03-11
RU2001126555A (en) 2003-06-20
RU2219912C2 (en) 2003-12-27
EP1181010A4 (en) 2003-03-26
AU4030800A (en) 2001-04-24
US7078052B2 (en) 2006-07-18
US20040180007A1 (en) 2004-09-16
EP1181010A1 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
US6465003B2 (en) Over-coated chewing gum formulations
US6322806B1 (en) Over-coated chewing gum formulations including tableted center
AU784112B2 (en) Pharmaceutical chewing gum formulations
US6773716B2 (en) Over-coated chewing gum formulations
US6613346B2 (en) Chewable product including active ingredient
US6426090B1 (en) Over-coated product including tableted center and medicament
US6627234B1 (en) Method of producing active agent coated chewing gum products
WO2000035296A1 (en) Improved release of medicament active agents from a chewing gum coating
US20020159956A1 (en) Over-coated chewing gum formulations
US7935362B2 (en) Over-coated product including consumable center and medicament
US20020110581A1 (en) Over-coated product including consumable center and medicament
AU779170B2 (en) Powder pharmaceutical formulations
AU765999B2 (en) Improved release of medicament active agents from a chewing gum coating
AU2001275945A1 (en) Over-coated chewing gum formulations including tableted center

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 40308/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 524582

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000919655

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2369515

Country of ref document: CA

Ref country code: CA

Ref document number: 2369515

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000919655

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 40308/00

Country of ref document: AU

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0009603

Country of ref document: BR

Free format text: PEDIDO RETIRADO FACE A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL POR TER SIDO INTEMPESTIVA. O PRAZO CIMITE PARA ENTRADA NA FASE NACIONAL EXPIRAVA EM 06.12.2000( 20 MESES - BR DESIGNADO APENAS), E A PRETENSA ENTRADA NA FASE NACIONAL SO OCORREU EM 08.10.2001.